 |
||
|
|
|
|
| Evidence-based pharmacotherapy of social anxiety disorder |
| Social anxiety disorder (SAD) is a highly prevalent and often disabling disorder. This paper reviews the pharmacological treatment of SAD based on published placebo-controlled studies and published meta-analyses. It addresses three specific questions: What is the first-line treatment of SAD? How lo |
| Evidence-based pharmacotherapy of Generalized Anxiety Disorder |
| Generalized Anxiety Disorder (GAD) is a common and often disabling disorder. This paper reviews the pharmacological treatment of GAD, based on the findings of published meta-analyses and randomized placebo-controlled studies. In doing so, it aims to address three fundamental questions: What is the |
| Blood pressure heart rate and anxiety in schizophrenia |
| Anxiety may worsen outcome in psychotic disorders. We assessed anxiety in 44 acutely psychotic subjects and found a positive association with heart rate and blood pressure. Risperidone treatment reduced anxiety but increased heart rate. We concluded that anxiety may adversely affect cardiovascular |
| Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders |
| BACKGROUND : The impact of anxiety disorders has not been well delineated in prospective studies of bipolar disorder. AIMS : To examine the association between anxiety and course of bipolar disorder, as defined by mood episodes, quality of life and role functioning. METHOD : A thousand t |
| Prospective Study of Posttraumatic Stress, Anxiety, and Depressive Reactions After Earthquake and Political Violence |
| Article;0] Prospective Study of Posttraumatic Stress, Anxiety, and Depressive Reactions After Earthquake and Political Violence Armen K. Goenjian, M.D. Alan M. Steinberg, Ph.D. LOLIIS M. Najarian. M.D. Lynn A. Fairbanks, Ph.D. Madeline Tashjian, Ph.D. Robert S. Pynoos. M.D. obctjv: The aut |
| What Is Worse for Asthma Control and Quality of Life-Depressive Disorders,Anxiety Disorders,or Both |
| CHEST Official publication of the American C ollege of Chest Physicians Kim L. Lavoie. Simon L. Bacon, Silvana Barone, Andre Cartier, Blame Ditto and Manon Labrecque Chest 2006:130:1039-1047 DCI 10.1378/chest.130.4.1039 The online version of this article, along with updated information and services |
| Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder |
| ORIGINAL ARI1CLE Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder Michael R. Lithowitz. MD; AlanJ. Geienberg. MD Dennis Munjack, MD Backgr.und: Evidence indicates that venlafaxine hydIoL hlorlde extended release (ER) effectively ameliorates anxiety symptoms. Obj. |
| Use of paroxetine for the treatment of depression and anxiety disorders in the elderly-a review |
| H LJMAN PSYCHOPHARMACOLOGY If urn Pswhopharrrzacol Clin Esj, 2003: III I 85—190. Puhlkhed online II December 2002 in Wiley InterScience twww.inter'.ience.iley.comt. 1101: I0.IOO2lhup.467 REVIEW Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: A review Mic |
| USE OF HEALTH SERVICES FOR MAJOR DEPRESSIVE AND ANXIETY DISORDERS IN FINLAND |
| D,arss, AND 4'.iiprr 0:1-11 2007,l 1?esc a/ ih A rticle USE OF hEALTH SERVICES FOR MAJOR DEPRESSIVE AND ANXIETY DISORDERS 1N FINLAND J. Hani?l?inen. M.D.. M.A.,”2 E. lsornctsà, Mi)., Ph.D..” S. Sihvo, PhD..4 S. Pirkola, M.D.. PhD..4 and 0. Kiviruuzsu. B.Soc.Sc' Factors associated with people r |
| Tryptophan Depletion Reverses the Therapeutic Effect of Selective Serotonin Reuptake Inhibitors in Social Anxiety Disorder |
| Tryptophan Depletion Reverses the Therapeutic Effect of Selective Serotonin Reuptake Inhibitors in Social Anxiety Disorder Spilios V. Argyropoulos, Sean D. Hood, Mariona Adrover, Caroline J. Bell, Ann S. Rich, Jon R. Nash, Neil C. Rich, Harry J. Witchel, and David J. Nutt Ikwkgrouiui: 7)flxc'phan |
| Treatment with medications affecting dopaminergic and serotonergic mechanisms-Effects on fluency and anxiety in persons who stutter |
| uriril 1 FLUENCY _____ DISORDERS LLSLVILR Journal of Fkncy Disorders 30(2005) 319—335 Treatment with mcdi cati ons affecting dopaminergic and serotonergic mechanisms: Effects on fluency and anxiety in persons who stutter Sheila V Stagera.*, Karim Calisb, Dale Grotheb, Meir BlochC Nannette NI |
| Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin |
| DRAL O AFFECTIVE DISORDERS iownal of Affective Disorders 86(2005)99-104 w.ckcvicr.comAocatajad Preliminary communication Treatment of residual anxiety symptoms with adju nctive aripiprazole in depressed patients taking selective serotonin reu ptake inhibitors David Ii. Adson*. Matt G. Kushn |
| Treatment of panic disorder with agoraphobia in an anxiety disorders clinic-factors influencing psychiatrists' treatment choices |
| Available online at www.sciencedirect.com BCIENC oEc'r PSYCHIATRY RESEARCH Psychiatry Research 125 (2004) 41—52 w Treatment of panic disorder with agoraphobia in an anxiety disorders clinic: factors influencing psychiatrists treatment choices Viadan StarcevicL*, Michael Linde&', E.H. Lthlenhu |
| Treatment of generalized anxiety disorder with citalopram |
| 8012580C Varia Poster 11/30/01 SzlE PM Page 1 TREATMENT OF GENERALIZED ANXIETY DISORDER WITH CITALOPRAM 91 I. Yada, F uflr, C. Cbulla, and J. GWOOL DqlarUnaH or PshbUy and taha4loral aMn, Dtke 0rlnrSll Modfl Carter, Dwlum, FZ USA Spel60r K. oarqa KoMrrrun MD. as.,. — ABSTRACT Ina'eda.üan: Srro, |
| Treatment of depression with comorbid anxiety disorders-differential efficacy of paroxetine versus moclobemide |
| Ongmaladlcle 15 Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide Stefano Rnia, Xavier F. Amadorb, Liliana DeIIOssoa, Nicole Baldini Ross, Paolo Cassanod, Mario Savinod and Giovanni B. Cassanod To compare the efficacy and tolerability |
| Treatment of depression and concomitant anxiety |
| Ft .SFVIF.R European Neuropsychophanmicology 10 (Suppl. 4) (2000) S433—S437 EUROPEAN NEURO. PSYNOPHARMACOLOGY www.elscvicr.com. locate. euroncuro Abst I'atl Treatment of depression and concomitant anxiety David Nun Psvchophor,nacologv (liii, School of M,'Jical Sciences, niversiry qf Bristol, |
| Treatment of anxiety and depressive disorders in patients with cardiovascular disease |
| Downloaded from brnJ.com on 16 August 2006 Treatment of anxiety and depressive disorders in patients with cardiovascular disease Simon J C Davies. Peter R Jackson, John Potokar and David J Nutt BMJ 2004:328:939-943 doi:1 0.1 136)bmj.328.7445.939 Updated information and services can be found at: htlp |
| Treating Patients for comobid depression,anxiety and somatic illnesses |
| 1) etween one third and two thirds of I) patients In the United States have significant depression as well as a vcixietv of comorhkl anxiety dLsorders, including: generalized anxiety disorder (GAD, 62%); obsessive compulsive disorder OCD, 27%); posttraurnatic stress disorder (PThD. 48%); social anxi |